Driver mutations in TP53 remain the main target of a not yet developed specific therapy in a wide range of progressing tumor such as breast, ovarian, uterine, lung, gastric cancers, oral, glioblastoma, and sarcoma (Figure 3). Here, TP53 is linked to neoplasm.